ISSN: 2231-3656

International Journal of Pharmacy and Industrial Research (IJPIR)

IJPIR |Vol. 16 | Issue 3 | Jul – Sep 2026

www.ijpir.com

DOI: https://doi.org/10.61096/ijpir.v16.iss3.2026.906-922

Nanocurcumin Capsules (Biotex Life Solutions): A Comprehensive Narrative Review of Pharmacokinetic Rationale, Antioxidant Mechanisms, Immunomodulatory Pathways, Safety Considerations, and Translational Evidence

Dr. Leroy Rebello[1], Dr. Sreesudha Chepyala[2] and Sahithi Polineni[3]

[1,2,3] *Department of Research and Development,*
Biotex Life Solutions Pvt. Ltd., Secunderabad, Telangana, India

*Corresponding author: **Polineni Sahithi**
E-mail: sahithi.biotexlife@gmail.com

Published on:

23.07.2026

Published by:

Futuristic Publications

2026| All rights reserved.

Creative Commons Attribution 4.0 International License.

Abstract: Curcumin, the major curcuminoid of Curcuma longa, has attracted nutraceutical, pharmacological and nanomedicine research for its diverse biological effects, but poor aqueous solubility, rapid metabolism, low systemic exposure and inter-preparation variability limit its utility. Nanosized curcumin improves solubility, cellular delivery and antioxidant, anti-inflammatory and immunomodulatory performance versus conventional curcumin. This narrative review of Nanocurcumin Capsules, a nano-engineered curcumin formulation from Biotex Life Solutions, links the product to mechanistic, pharmacokinetic and clinical evidence to support claim-safe nutraceutical positioning around antioxidant reinforcement, healthy inflammatory balance and immunomodulation. The strongest mechanistic evidence for nanocurcumin includes direct radical scavenging, Nrf2/HO-1 activation, NF-κB suppression, and regulation of TLR4/NLRP3 signalling. Pharmacokinetic data indicate improved bioavailability with nanoformulation, though performance depends on carrier, particle size and manufacturing; robust product-level claims additionally require documentation of curcuminoid content, particle size, formulation robustness and excipient safety across batches. On current evidence, Nanocurcumin Capsules can be positioned as a bioavailability-enhanced curcumin product with antioxidant, anti-inflammatory and immunomodulatory properties, but not as a treatment for any disease. The review identifies translational limitations and priorities for product-specific pharmacokinetic and clinical studies.

Keywords: Nanocurcumin; curcumin; bioavailability; antioxidant; immunomodulation

1. Introduction

1.1 Scientific Context: Curcumin as a Nutraceutical Molecule

Curcumin (1, 7-bis (4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-Dione) is a diferuloylmethane polyphenol extracted from the rhizome of Curcuma longa L. and reported to have a wide range of pharmacological activities [1, 21]. Its biological activity is mainly determined by the redox properties of the phenolic hydroxyl groups at positions 4 and 4′, keto-enol tautomerism, interactions with NF-κB and Nrf2 transcription factors, and regulation of intracellular signal transduction cascades [25–27]. Curcumin is the major curcuminoid in C. longa, comprising 77% of the curcuminoids, with demethoxycurcumin and bisdemethoxycurcumin accounting for 17 and 3%, respectively [3]. Curcumin was reported to demonstrate

antioxidant, anti-inflammatory, immunomodulatory, neuro- and cardio-protective effects and influence the progression of several diseases [21, 27].

1.2 The Pharmacokinetic Problem: Why Native Curcumin Fails in Translation

The main limitation of native curcumin in terms of clinical translation is its poor aqueous solubility (about 11 ng/mL at physiological pH) and, consequently, low oral bioavailability [1, 3]. Following oral administration, curcumin undergoes extensive O-glucuronidation and sulfation in the intestine and liver, resulting in rapid biliary and faecal excretion and low systemic exposure [2,3]. As a result, curcumin concentrations in plasma following oral dosing are below 10–50 ng/mL, while the majority of curcumin is present in the form of sulfate and glucuronide conjugates with reduced biological activity [2,3]. Therefore, the bioavailability of curcumin is significantly limited, making the comparison of clinical outcomes between different curcumin products challenging [3, 4].

1.3 Nanocurcumin as a Solution Category

Nano-curcumin is a broad class of curcumin formulations with improved pharmacokinetic performance, allowing enhanced cellular delivery [4, 5, 7]. Nanocurcumin can be manufactured as polymeric nanoparticles [4,5,28–31], solid lipid nanoparticles [4,5,32,33], nanostructured lipid carriers [4,34,35], liposomes [4], micelles [4,36–38], nanoemulsions [4,39,40], polysaccharide conjugates and hyaluronic-acid-based nanoforms [4,5], and other systems [5].

1.4 Rationale for This Review

The objective of this publication is to develop a product-level narrative review of Nanocurcumin Capsules, Biotex Life Solutions, with a focus on the evidence required to substantiate claims about antioxidant support, healthy inflammatory balance, and immunomodulation [9,10], by linking the product literature to mechanistic preclinical and clinical evidence [8–10,12–18], formulation performance aspects [5,7,23], and translational limitations for inflammatory, degenerative, and autoimmune diseases [1,26].

2. Methodology

This manuscript was developed as a product-level narrative review based on the published literature, reorganised into this publication's structure for submission as a publication-ready review for academic or regulatory audiences [4, 8, 10]. The literature was grouped according to the themes relevant to the product, namely: overall bioavailability, formulation aspects, antioxidant, anti-inflammatory, immunomodulatory mechanisms, clinical evidence, safety, standardisation, and claim substantiation [5,9,13,23]. The literature search was performed using PubMed/MEDLINE, Scopus, Web of Science, google scholar and the Cochrane Central Register of Controlled Trials, using the following search terms: Curcuma longa, curcumin, nanocurcumin, curcumin nanoparticles, curcumin nanoformulation, curcumin bioavailability, Nrf2/HO-1, NF-κB, NLRP3, TLR4, curcumin immunomodulation, curcumin antioxidant, polymeric nanoparticles, lipid, micellar curcumin, PLGA curcumin [3,4,16,23,32]. Review articles, mechanistic studies, nanoformulation literature, pharmacokinetic studies, randomised evidence when available, and relevant translational studies were included in the search [3,4,16,23,32]. The review follows the distinction between evidence for curcumin as a molecule, nanocurcumin as the formulation category, and evidence for a specific commercial product, such as BiotexLife Nanocurcumin Capsules [4,10,19]. This is an important distinction because specific scientific claims about a commercial product cannot be derived from the literature on curcumin without considering the characteristics of the specific formulation [3,18,23]. The current review avoids making treatment, prevention, cure, or disease-modification claims in relation to chronic inflammatory, autoimmune, hepatic, respiratory, oncological, or metabolic disorders [17, 21, 34].

3. Product Context: BiotexLife Nanocurcumin Capsules

3.1 Scientific Positioning of the Product

Bioavailability-enhanced curcumin is a nutraceutical formulation that can be positioned according to the literature on nanocurcumin [8, 10]. Evidence for Nanocurcumin Capsules, BiotexLife Solutions, can be developed based on a literature review about the benefits of nanoformulation for curcumin in terms of its bioavailability, antioxidant, anti-inflammatory, and immunomodulatory properties [4, 12–15].

3.2 Technical Documentation requirements

For technical documentation purposes, literature evidence should include technical descriptions of the product to support its characterisation, establish its safety and quality, and ensure the consistency of its

performance across batches. This includes evidence on the source of the raw material (Curcuma longa), curcumin assay, particle size, zeta potential, polydispersity index, carrier or excipient composition, microbial and contaminant testing, residual-solvent profiling, stability, and batch-to-batch consistency [7,19,20,24]. These are essential considerations for a product-level review because nanoformulation performance is strongly dependent on the choice of the carrier material, particle size and surface properties, and the manufacturing process [24,35,36]. In the absence of detailed technical documentation on the product, the strongest formulation-related evidence is that the product follows the general trends of the nanoformulation literature and should be subjected to additional product-specific studies [3, 23, 37].

Table 1: Summary of BiotexLife Nanocurcumin Capsules

Parameter	Details
Product Name	Nanocurcumin Capsules
Manufacturer	BiotexLife Solutions Private Limited
Product Category	Botanical Nutraceutical / Dietary Supplement
Active Ingredient	Curcumin (nanoformulated from Curcuma longa rhizome)
Delivery Form	Capsule (nano-engineered delivery matrix)
Primary Claim	Antioxidant support, healthy inflammatory balance, immune homeostasis
Target Population	Health-conscious adults seeking antioxidant and anti-inflammatory wellness support
Regulatory Category	Nutraceutical / botanical dietary supplement (not a pharmaceutical)
Positioning Statement	Bioavailability-oriented curcumin formulation for antioxidant and immune wellness

4. Rationale for Nanoformulation

4.1 The Bioavailability Gap

Nanoformulation can help increase curcumin's oral bioavailability, which is limited by its poor aqueous solubility and extensive first-pass metabolism [1, 3]. The rationale for nanoforming curcumin is to improve its pharmacokinetics and, therefore, therapeutic efficacy [4,5,28]. Nanoparticles increase the surface area of curcumin, thus enhancing its solubility and improving its dispersion in the gastrointestinal tract [5]. Nanoformulation can also help prevent curcumin's rapid intestinal and hepatic metabolism, thereby enhancing its systemic exposure and biological effects [4, 5].

4.2 Nanocarrier Platform Options and Their Relevance

Polymeric, lipidic and micellar systems, among others, can be used to deliver curcumin as nanoparticles, nanomicelles or nanostructured lipid carriers [28, 29, 31]. The choice of the excipient affects the performance of curcumin nanoformulations [28, 29, 31]:

Solid-lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): may improve oral bioavailability by facilitating lipid solubility and targeting lymphatic absorption to bypass hepatic first-pass metabolism [28, 47, 48].

Polymeric nanoparticles (PLGA, chitosan, albumin): allow for targeted delivery and control over the release rate but require optimisation of the physicochemical properties, including size, surface charge, and hydrophilic-lipophilic balance [49–51].

Micellar and conjugated systems: increase the aqueous solubility of curcumin and facilitate dispersion in the gastrointestinal tract [52–54].

4.3 Performance Requirements for a Nano-Superiority Claim

When making claims for a nano-superiority of a curcumin formulation, such as BiotexLife Nanocurcumin Capsules, its performance should be compared to conventional curcumin or curcumin powder products at the equivalent dose [4, 17, 23, 37]. At a minimum, such evidence should include dissolution studies, particle size analyses, curcumin assays, and, if available, clinical studies in relevant populations [3,28,50]. In the

absence of comparative clinical studies, a nanocurcumin product should not make claims about its superiority over conventional curcumin [17, 20].

5. Pharmacokinetic and Bioavailability Considerations

5.1 Native Curcumin Pharmacokinetic Limitations

Improved bioavailability is the key claim for nanocurcumin products because curcumin's native solubility and stability are limited [1,3]. Following oral administration, curcumin is subject to extensive first-pass metabolism, resulting in rapid biliary and faecal excretion and low systemic exposure [2–4]. As a result, curcumin has poor oral bioavailability with Cmax values below 50 ng/mL after single oral doses of 2–8 g [2,3]. At the same time, curcumin is subject to extensive metabolic conversion in the liver and intestines, with most of the curcumin in the systemic circulation being present as sulfate and glucuronide conjugates with reduced biological activity [2, 3].

5.2 Nanoformulation Enhancement Mechanisms

Nanoformulation can enhance the bioavailability of curcumin by increasing its solubility in aqueous fluids, thus improving its dispersion and absorption [5, 7, 48]. Other mechanisms of nanoformulation include protection from metabolic degradation, facilitated cellular uptake, altered biodistribution, and reduced first-pass metabolism [3,22,42]. These principles have been demonstrated in multiple preclinical studies using polymeric or lipid nanoparticles, nanostructured lipid carriers, or other delivery systems [35, 36, 50].

5.3 Product-Specific Pharmacokinetic Priorities

The key pharmacokinetic consideration for BiotexLife Nanocurcumin Capsules includes the evidence on the comparative bioavailability of the product, which can be demonstrated by clinical studies with the curcumin formulation [3, 23, 37]. These studies can include pharmacokinetic profiling of curcumin in healthy volunteers following a single oral dose to determine the Cmax and AUC, assess the degree of curcumin conjugation, and evaluate the differences in urinary excretion of curcumin between the test and reference products [5,7]. Pharmacokinetic evidence would become critical to support the claims about improved absorption, lower effective dose, and enhanced cellular delivery of curcumin [4, 17, 23].

Notably, the pharmacokinetic performance of one nanocurcumin product cannot be extrapolated to another because of the variability in formulation approaches [7, 18, 29]. Therefore, the literature evidence should be used to develop the claims for the specific product while taking into account the limitations of the formulation. For example, the differences in bioavailability between BiotexLife Nanocurcumin Capsules and conventional curcumin may depend on the manufacturing process, excipient composition, and formulation techniques used [3,19]. It is essential to ensure that the formulation of Nanocurcumin Capsules follows the general principles of nanoforming described above to achieve the anticipated improvements in curcumin's bioavailability [24, 35, 36].

Table 2: Requirements to Substantiate a Nanocurcumin Capsule Product

Evidence Layer	Purpose	Recommended Product-Specific Output
Identity and assay	Confirms active compound and curcuminoid profile are controlled	Curcumin/curcuminoid HPLC assay, chromatographic fingerprint, source authentication, batch certificate [3,21]
Nanoformulation characterization	Confirms formulation is truly nano-engineered and reproducible	Particle-size distribution, PDI, zeta potential, morphology, encapsulation efficiency, release profile [7,24,35]
Bioavailability or bioaccessibility	Confirms nanoformulation improves delivery vs. curcumin	In vitro dissolution, simulated GI studies, Caco-2 or ex vivo models, human PK where feasible [2,23,50]

Mechanistic biomarker support	Links formulation behaviour to antioxidant and inflammatory-balance pathways	ROS, MDA, SOD, GPx, GSH, Nrf2/HO-1, NF-κB, cytokines, TLR4/NLPR3 endpoints [12,14,38,55]
Safety and quality	Supports consumer use and publication credibility	Microbial testing, heavy metals, residual solvents, excipient safety, stability, adverse-event monitoring, interaction assessment [18–20]

6. Antioxidant Mechanisms Relevant to Product Positioning

6.1 Direct Radical Scavenging

Antioxidant support is one of the most relevant mechanistic aspects of BiotexLife Nanocurcumin Capsules, as curcumin is a phenolic compound with intrinsic radical scavenging activity [12, 26, 38]. The antioxidant activity of curcumin can be demonstrated in vitro by its ability to inhibit lipid peroxidation of membrane lipids and the formation of protein carbonyl groups [44,45]. Curcumin is a redox-active compound that can donate electrons from its enol and aromatic OH groups and participate in hydrogen atom transfer reactions by virtue of the presence of the central CH2 group [26,39,56]. Both the phenolic OH groups and ketone groups of curcumin participate in antioxidant defence mechanisms [26,57]. Specifically, the enolic hydrogens of curcumin are involved in radical stabilisation, while the ketone oxygen coordinates with transition metals to suppress their ability to catalyse oxidation reactions [26,39,56]. Nanoencapsulation can enhance direct radical scavenging by curcumin by virtue of increased surface area and better dispersion in the gastrointestinal tract and cellular compartments [5, 57, 58].

6.2 Nrf2/HO-1 Axis Activation

The Nrf2/HO-1 (Nuclear factor erythroid 2-related factor 2 / Heme oxygenase-1) pathway is a key endogenous antioxidant system that can be activated by curcumin treatment [38, 39, 59]. Nrf2 is a transcription factor that regulates the expression of antioxidant and detoxifying enzymes upon exposure to oxidative stress [38,39,59]. Activation of Nrf2 by curcumin leads to induction of HO-1, NQO1, GCL, and other antioxidant-responsive genes that play a protective role in various models of disease [38,59]. Nano-curcumin can enhance the antioxidant response by virtue of improved delivery of curcumin to target tissues [14,55].

6.3 Lipid Peroxidation, Antioxidant Enzymes, and Mitochondrial Protection

Preclinical studies with nanocurcumin can support antioxidant mechanisms by linking curcumin treatment to decreases in lipid peroxidation end-products, such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), and increases in total antioxidant capacity (TAC) and activities of antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) [40,60,61]. Curcumin nanoparticle-conjugates in PBAE nanogels have demonstrated enhanced mitochondrial protection against oxidative stress in cultured cells, indicating that the combination of nanodelivery and curcumin redox activity can effectively ameliorate oxidative stress at the cellular level [62]. Thus, nanocurcumin has been shown to exert protective effects in various preclinical models of oxidative stress by regulating ROS production and mitochondrial membrane potential [34,39,62]. This evidence can be used to support the antioxidant mechanism of the BiotexLife Nanocurcumin Capsules, although its relevance to human consumer application requires additional confirmation.

As stated elsewhere, nanoformulation has been shown to improve antioxidant effects of curcumin, particularly through enhanced regulation of the Nrf2 pathway [12,38]. Therefore, the product literature evidence should be used to develop the claims for Nrf2/HO-1 activation. In particular, the product-level statement could be: “Supplemental curcumin in the form of Nanocurcumin Capsules promotes antioxidant balance and supports cellular health by regulating Nrf2-mediated pathways.” This evidence can be supported by the preclinical and clinical studies demonstrating that nano-curcumin formulation increases ROS scavenging capacity and downregulates oxidative stress markers including MDA, 4-HNE, and NF-κB in various models of disease [12,38].

7. Inflammatory-Balance and NF-κB Pathway Modulation

7.1 NF-κB as the Central Inflammatory Transcription Factor

The relevance of curcumin to inflammation derives predominantly from its ability to regulate NF-κB, COX-2, iNOS, MAPK, TLR4/MyD88, and cytokine-dependent signalling cascades [13–15,41]. Nuclear factor NF-κB is considered a master transcription factor that controls the expression of proinflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8), adhesion molecules, and inducible inflammatory enzymes (COX-2, iNOS). Curcumin has been consistently investigated in relation to the inhibition of NF-κB pathway signalling in murine and cellular models of inflammation [13,14,27]. Nanostructured delivery appears to enhance the relevance of curcumin to inflammatory-balance control by targeting the compound to immune, epithelial, and endothelial cells to modulate NF-κB-regulated gene expression [4,9,63].

7.2 TLR4/MyD88 Axis

The TLR4/MyD88/NF-κB signalling axis provides a mechanistic link between pattern-recognition-receptor-triggered innate immunity and NF-κB-dependent inflammation [15,55]. Several curcumin/nanocurcumin studies demonstrate suppression of TLR4/NF-κB signalling, with reduced production of TNF-α, IL-1β, and IL-6, downregulation of the key adaptor molecule MyD88, and attenuation of the NF-κB p65 subunit nuclear translocation [14,15,63]. Notably, nano-curcumin was shown to suppress TLR4 and TLR2 expression and activity in murine macrophages while inducing an anti-inflammatory shift in macrophage polarisation [63]. This line of evidence supports the application of nanocurcumin in the maintenance of healthy inflammatory balance but does not establish therapeutic efficacy against inflammatory disease [13,17,32].

7.3 NLRP3 Inflammasome Regulation

A similar conclusion can be drawn with regard to the NLRP3 inflammasome mechanism, which translates the signal from stress-inducing molecules (ROS, ATP, uric acid, fatty acids) into caspase-1-mediated IL-1β and IL-18 production [64,65]. Suppression of the NLRP3 inflammasome has been reported for nano-curcumin in studies investigating lung epithelial cells and experimental colitis [64,66]. In turn, this contributes to the overall anti-inflammatory effect of curcumin through the attenuation of IL-1β and other cytokines driving the inflammatory cascade [14,15].

Thus, the mechanistic relevance of BiotexLife Nanocurcumin to the maintenance of healthy inflammatory balance emerges as a plausible consideration, given its interactions with a variety of inflammatory-signalling pathways and suppression of NF-κB-regulated gene expression.

Table 3 summarises the key inflammatory-signalling pathways affected by curcumin/nanocurcumin.

Table 3: Key Inflammatory Signalling Pathways Affected by Nanostructured Curcumin

Pathway	Curcumin/Nanocurcumin Effect	Mechanistic Relevance	Evidence Level
NF-κB (p65 subunit)	IKK inhibition; decreased IκBα phosphorylation; decreased nuclear NF-κB translocation	Reduced TNF-α, IL-1β, IL-6, COX-2, iNOS transcription	In vitro, animal, early clinical
TLR4/MyD88	Decreased TLR4/TLR2 expression and activity; decreased MyD88 signaling	Reduced innate immune cytokine cascades	In vitro, animal models
NLRP3 inflammasome	Decreased NLRP3 assembly; decreased caspase-1 activity; decreased IL-1β maturation	Reduces pyroptosis-related inflammation	In vitro, animal models
Nrf2/HO-1 (cross-talk)	Increased Nrf2 nuclear translocation; increased ARE gene expression; decreased ROS	Antioxidant defence suppresses inflammatory trigger	In vitro, animal, limited human

MAPK (JNK, ERK, p38)	Modulation of kinase phosphorylation cascade	Reduced AP-1-mediated pro-inflammatory gene expression	In vitro models

8. Immunomodulatory Relevance and Immune Homeostasis

8.1 Distinguishing Immune Modulation from Immune Stimulation

The immunomodulatory relevance of BiotexLife Nanocurcumin Capsules may be considered within the established framework describing curcumin's interaction with immune cells. Notably, curcumin does not demonstrate an "immune stimulating" profile, but rather appears to modulate excessive inflammation at multiple levels of regulation, including inhibition of NF-κB, COX-2, TLR4/MyD88, and cytokine signalling [16,42,43]. Nano-delivery enhances the immunomodulatory effects of curcumin by improving its bioavailability and cellular penetration [4,16]. Thus, the overall effect of BiotexLife Nanocurcumin Capsules on the immune system should be qualified as immunomodulatory and potentially beneficial to immune homeostasis but without direct implications for the treatment or prevention of infection or immune dysfunction [17,44].

8.2 Macrophage Polarisation and Cytokine Networks

From the mechanistic perspective, the immunomodulatory effects of nano-curcumin may primarily affect macrophage polarisation and cytokine networks, with a potential shift towards a more regulatory (M2-like) immune response [16,42,43,63]. In addition, curcumin has been shown to inhibit TLR signalling in dendritic cells and modulate Th17/Treg cell balance, including reduced IL-17 production and FoxP3 induction [16,32,42]. Nanostructured delivery of curcumin was shown to increase cellular uptake while reducing inflammation in murine models of macrophage activation [63].

8.3 Clinical Translation: Immune-Modulator Claims

A clinical study by Karimi et al. (2022) provides evidence for the beneficial effect of curcumin nanomicelles on the outcome of severe sepsis by reducing cellular inflammation [16]. A review article by Arab et al. (2024) discusses the immunoregulatory properties of nano-curcumin and its relevance to inflammatory disease settings [17]. Thus, the clinical translation of the immunomodulatory effects of BiotexLife Nanocurcumin Capsules appears to be supported by the available literature, including the clinical study by Karimi et al. (2022).

The overall interpretation of the clinical effects of nano-curcumin should emphasise its potential to participate in the maintenance of immune homeostasis, with references to cytokine networks and T cell regulation. Claims related to boosting or stimulating the immune system should be avoided due to the regulatory and scientific complexity of such statements [17,44].

9. Joint, Cardiometabolic, and Systemic Wellness Research Context

9.1 Joint Comfort and Inflammatory Balance

The research literature supports the value of curcumin in joint health and comfort due to its ability to affect inflammatory mediators, including TNF-α, IL-1β, IL-6, and PGE2, which are frequently involved in joint discomfort, cartilage, and synovial membrane inflammation [32,45]. Zeng et al. (2022) performed a systematic review and meta-analysis of clinical studies on curcumin and found that the compound and its extract (from Curcuma longa) were associated with improved joint discomfort in multiple randomised controlled trials [32]. In turn, nano-curcumin provides additional support for the role of curcumin in joint health due to improved bioavailability and targeted delivery [32,45]. Thus, BiotexLife Nanocurcumin Capsules may be considered a viable option for the support of joint health and maintenance of joint inflammatory balance.

9.2 Cardiometabolic Wellness

The cardiometabolic relevance of curcumin is well-established in the literature due to the compound's interactions with oxidative stress, inflammatory pathways, lipid metabolism, and glucose regulation [33,40,46]. In turn, Sun et al. (2026) have reviewed the role of curcumin in cardiometabolic wellness with a specific focus on metabolic regulation in multiple tissues [33]. Nanocurcumin appears to enhance the cardiometabolic effects of curcumin by improving its bioavailability and influencing oxidative stress and

inflammatory cascades [40]. Thus, nano-curcumin may contribute to multiple aspects of cardiometabolic wellness, including vascular, metabolic, and hepatic functions [33,40,46].

9.3 Systemic Wellness Context

The systemic nature of the mechanisms and the supportive clinical evidence across multiple areas of health make the cardiometabolic context for curcumin and its nano-formulated derivatives particularly appealing from the scientific publishing perspective. Specifically, the oxidative stress/inflammatory pathways are the key regulators of vascular, hepatic, metabolic, immune, and musculoskeletal functions, and their disruption is implicated in the development of multiple diseases [33,68]. Thus, nano-curcumin can be considered within the systemic wellness context with emphasis on the maintenance of physiological function across multiple areas of health. This approach would simultaneously highlight the disease prevention/value health aspects of BiotexLife Nanocurcumin Capsules while avoiding direct disease treatment claims [9,10,17].

10. Safety, Tolerability, and Responsible Use

10.1 Distinguishing Nanocurcumin Safety from Traditional Turmeric Safety

Turmeric and curcumin have been used as dietary spices/herbs for centuries with a demonstrated safety profile, although the nanoformulation approach affects the pharmacokinetics and may impact safety in significant ways. Thus, the safety considerations for BiotexLife Nanocurcumin Capsules may not always align with the expectations based on the traditional use of turmeric or even conventional curcumin supplements [18,21,22]. Nanoencapsulation increases the systemic exposure to curcumin and allows targeting of specific tissues, which may improve efficacy but also impact tolerability and safety [3,18,23]. Therefore, the safety assessment for nanocurcumin should take into account the potential differences from conventional curcumin formulations and dietary turmeric.

10.2 Principal Safety Considerations

The most common safety concerns for curcumin nanoformulation-based dietary supplements include:

- Gastrointestinal tract discomfort due to increased bioavailability and absorption
- Increased anti-platelet and anti-coagulant effects with potential interactions with anti-thrombotic medications
- Choleretic effects and potential contraindications in patients with gallbladder disease
- Drug-drug interactions due to CYP inhibition
- Special considerations in pregnancy, breastfeeding, and patients with hepatic impairment

Nano-curcumin appears to be generally well-tolerated, with dose-dependent gastrointestinal discomfort being the most common concern. At the same time, curcumin possesses anti-thrombotic properties that may interact with anti-platelet and anti-coagulant medications, and choleretic effects that may need to be considered in patients with gallbladder disease [18,21,22]. Additionally, nano-curcumin may inhibit CYP enzymes (CYP1A2, CYP3A4, CYP2C9), and caution should be exercised in patients receiving CYP-modulating therapeutics [18,20].

Product-specific safety considerations should also highlight the potential interactions between nanocurcumin and prescription medications, including anti-thrombotics and CYP inhibitors/inducers. The use of BiotexLife Nanocurcumin Capsules should be discouraged in pregnancy due to the potential fetotoxic effects of curcumin and nano-curcumin [18,21,22].

10.3 Publication-Ready Safety Documentation

For publication purposes, BiotexLife should be prepared to provide documentation on the safety assessment of nanocurcumin. First and foremost, it is important to emphasise good manufacturing practices (GMP) and quality control (QC) for the nanocurcumin capsules, including the specification and validation of excipients used in the nano-formulation [19,20,24]. Second, the safety documentation should include batch-specific release tests for curcumin assay, particle size analysis, endotoxin content, microbiological purity, heavy metals, and other applicable tests. Third, the manufacturer should be able to comment on the tolerability of its nanocurcumin formulation based on clinical trials or the published

evidence in the field. Fourth, the excipient safety should also be discussed, including potential sensitization and regulatory categorization of the materials used to deliver nano-curcumin [7,20,49].

According to the Risk Assessment study by Rahim-Mahdy and Seifert (2025), the safety documentation for turmeric supplements is highly inconsistent between manufacturers, with significant variation in quality and risk factors across brands [18]. Therefore, it is advisable for BiotexLife to follow the GMP guidelines and be transparent about the quality control procedures, including QC analysis of each nanocurcumin batch, prior to publication or large-scale distribution [19,24].

11. Manufacturing and Quality-Control Requirements

11.1 Manufacturing Consistency as a Determinant of Product Claims

Nano-formulation presents consistent challenges in the manufacturing process, making the quality-control procedures especially relevant for the publication-ready product claims. In particular, microfluidic mixing technologies are utilised in the production of nanocurcumin to provide greater consistency between batches [24,69,70]. Valencia et al. (2013) describe combinatorial microfluidic synthesis as a tool for optimising nanoparticle formulation by reducing inter-batch variability [70]. Kamaly et al. (2012) discuss the physicochemical considerations for nano-formulated therapeutics, including the importance of microfluidic mixing for controlling particle size distribution and polymer-to-drug ratios [69].

11.2 Quality-Control Release Specifications

The following product specifications may be considered for the quality control and release of BiotexLife Nanocurcumin Capsules:

- Assay of the curcuminoids (curcumin content)
- Appearance, optical properties, capsule weight
- Moisture content
- Particle size distribution (D10, D50, D90), surface zeta potential, polydispersity index (PDI), and other physicochemical characteristics
- Encapsulation efficiency
- Microbial load and endotoxin content
- Heavy metals
- Pesticide residues and aflatoxins
- Residual solvent content
- Stability under accelerated and real-time conditions
- Compatibility with packaging material

For the publication-ready product review, the emphasis will be on manufacturing consistency, formulation optimisation, and analytical batch certification. In particular, it will be important to ensure that the nanocurcumin formulation is produced using standardised and reliable methods with minimal inter-batch variability. In turn, the manufacturing specifications and QC procedures will serve as the foundation for the publication-ready claims on curcumin nanoformulation [19,20,23].

12. Translational Evidence and Publication Positioning

The literature provides robust evidence for the value of nano-curcumin as a tool for improving the pharmacokinetics and biological availability of curcumin and highlights its relevance to antioxidant support, inflammatory-balance modulation, and immune homeostasis [4,9,10]. Karthikeyan et al. (2020), Laurindo et al. (2023), and Rigia et al. (2025) review the literature and discuss the therapeutic potential of various nano-curcumin formulations [4,9,10]. Boroughani et al. (2024) provide a focused review of the

evidence for nano-curcumin in oncology, while Arab et al. (2024) discuss the immunomodulatory effects of nano-curcumin [17,34].

Thus, the available literature supports the value of nano-curcumin, including its ability to enhance the pharmacokinetics of curcumin, improve antioxidant and anti-inflammatory effects, and influence multiple disease pathways.

Table 4 provides an overview of the evidence basis and suggested claim positioning for BiotexLife Nanocurcumin Capsules.

Table 4: Product-Oriented Evidence and Claim-Positioning Matrix for BiotexLife Nanocurcumin Capsules

Claim Area	**Scientifically Safer Wording**	**Evidence Basis**	**Caution for Publication and Labelling**
Antioxidant support	"Supports antioxidant defence and helps protect cells from oxidative stress"	Curcumin and nanocurcumin literature supports ROS modulation, lipid-peroxidation control, Nrf2/HO-1 activation, and endogenous antioxidant enzyme support [12,38–40]	Avoid claiming treatment of oxidative-stress diseases unless product-specific clinical evidence exists [17,34]
Healthy inflammatory balance	"Helps maintain a healthy inflammatory response"	Curcumin modulates NF-κB, COX-2, iNOS, TLR4/MyD88, MAPK, and cytokine signalling in mechanistic models [13–15,41]	Avoid disease-specific anti-inflammatory treatment claims such as arthritis, IBD, asthma, or autoimmune disease treatment [32]
Immune homeostasis	"Supports immune-system balance and normal immune signalling"	Evidence supports modulation of macrophage polarisation, T-cell balance, cytokine release, and innate immune signalling [16,17,42,43]	Do not present the product as an immune booster or infection-prevention agent [17,44]
Joint comfort research	"May support joint comfort by helping maintain inflammatory balance"	Curcumin and Curcuma longa extract trials and reviews support joint-symptom relevance; nanocarrier models suggest improved local inflammatory modulation [32,45]	Avoid claims of rheumatoid arthritis or osteoarthritis treatment without product-specific clinical trials [32]
Cardiometabolic wellness	"Supports systemic wellness pathways related to oxidative and inflammatory balance"	Curcumin literature links redox and inflammatory modulation with metabolic and vascular signalling pathways [33,40,46]	Avoid claims for diabetes, dyslipidemia, cardiovascular disease, or NAFLD treatment without direct clinical evidence [21,22]

13. Limitations

The main limitation of this publication-ready review is the general applicability of the provided information to any particular nanocurcumin capsule product. Most of the literature findings relate to curcumin or nano-curcumin in general rather than a specific finished product, such as BiotexLife Nanocurcumin Capsules in particular. Thus, the findings may serve as a general guide for developing publication-ready claims but cannot be directly applied to any particular product without further product-specific evidence.

A second limitation that should be acknowledged is related to the potential for extrapolation of the mechanism-oriented findings to disease treatment areas. While the findings from in vitro and animal

studies provide a strong theoretical basis for discussing the antioxidant and anti-inflammatory effects of nano-curcumin, they do not establish clinical efficacy for treating or preventing any disease [13,17,34]. This review intentionally avoids treatment-oriented claims and focuses on the general wellness aspects of curcumin nano-delivery.

Finally, the findings of this review apply to nano-curcumin in general and nano-curcumin capsules in particular. The degree to which the findings apply to various nano-curcumin formulations will depend on the similarities between the products. Since the differences between the nanoformulations may be significant at the level of formulation and particle characteristics, extrapolation of the findings to different formulations may be limited [7,19,29].

14. Future Research Priorities for Nanocurcumin Capsule Products

Table 5 below outlines the major research priorities for the nanocurcumin capsule product.

Table 5: Proposed Research Framework for Nanocurcumin Capsule Products

Priority	Study Type	Objective	Key Endpoints
1. Product monograph	Analytical / formulation characterization	Define finished-product identity, curcuminoid assay, particle characteristics, stability, excipient safety.	Curcuminoid HPLC, PDI, zeta potential, release profile, batch CoA [3,7,19]
2. Bioaccessibility study	In vitro dissolution / simulated GI model	Compare nano vs. native curcumin dissolution and bioaccessibility	Dissolution rate, simulated GI stability, Caco-2 permeability [2,23,37]
3. Human pharmacokinetic study	Open-label crossover PK (healthy volunteers)	Confirm enhanced bioavailability vs. conventional curcumin	AUC, Cmax, Tmax, t½, free vs. conjugate curcumin plasma profiling [2,3,23]
4. Antioxidant biomarker study	Randomised, double-blind, placebo-controlled (healthy adults, n=40–60)	Confirm mechanistic alignment with antioxidant-defence claims	MDA, TAC, SOD, GPx, GSH, Nrf2/HO-1, tolerability [12,38,40]
5. Inflammatory balance study	Randomised, double-blind, placebo-controlled (adults with metabolic wellness concern, n=60–100)	Evaluate inflammatory-balance maintenance over 8–12 weeks	CRP, TNF-α, IL-6, IL-1β, NF-κB activity, safety, tolerability [13–15,32]
6. DPP-4/interaction profiling	In vitro CYP panel and transporter assay	Characterise drug interaction risk for the nanocurcumin formulation	CYP1A2, CYP3A4, CYP2C9, P-gp interaction [18,20]
7. Long-term safety surveillance	Post-market surveillance (12–24 months)	Monitor repeat-use safety, track adverse events	Adverse event frequency, hepatic panel, GI tolerability, interaction signals [17,18,20]

As the evidence base for nanocurcumin capsules continues to accumulate, the focus of scientific publishing should shift towards human studies that explore the clinical implications of improved antioxidant and anti-inflammatory effects. Ideally, such studies would utilise a randomised, double-blind, placebo-controlled

design, allowing for the objective evaluation of the effects of BiotexLife Nanocurcumin Capsules with regard to antioxidant biomarkers, inflammatory-balance mediators, and joint comfort indications [21,32,33].

While disease treatment studies would greatly benefit from the inclusion of nano-curcumin, such research would require substantial funding, institutional support, and regulatory approval, which may currently be unavailable for a nutraceutical product. A safer alternative for short- to medium-term evidence generation is the study of inflammatory-balance maintenance in adults with risk factors using a moderate sample size (n=60–100) and biomarkers of interest (CRP, TNF-α, IL-6, IL-1β, NF-κB activity, etc.) [13–15,32].

Finally, post-market surveillance is essential for all supplement products, including nanocurcumin capsules. About BiotexLife Nanocurcumin Capsules specifically, such surveillance should monitor long-term tolerability and identify potential pharmacokinetic interactions, especially in patients receiving CYP-modulating therapeutics [17,18,20].

15. Conclusion

BiotexLife Nanocurcumin Capsules represent a strategically formulated nutraceutical product that targets the known limitations of curcumin in terms of aqueous solubility, cellular penetration, and metabolic stability. The peer-reviewed literature provides substantial evidence for the value of nano-curcumin in antioxidant defence, maintenance of inflammatory balance, and immune-system homeostasis, with a variety of preclinical studies supporting the compound's mechanistic relevance to these areas of health [12–15,38,40,43]. These findings can help position BiotexLife Nanocurcumin Capsules as a scientifically substantiated nutraceutical with conservative but meaningful statements related to antioxidant, inflammatory-balance, and immune-system support. However, disease-treatment and cure-related statements should be avoided unless supported by product-specific clinical trials [17,21,34].

To prepare for a publication-ready product claims review, BiotexLife should compile the evidence base on the pharmacokinetics, formulation characteristics, and safety aspects of nano-curcumin. In particular, the company should be prepared to comment on the bioavailability of nano-curcumin, compare it to conventional curcumin and dietary turmeric, discuss the excipient safety, and provide evidence on tolerability and biomarker effects. Having addressed these points, BiotexLife will be able to publish a comprehensive product review, including a publication-ready claims analysis, that will serve as a useful tool for clinicians and researchers alike [9,10,19].

Declarations

Funding

This product review was performed to generate scientific evidence for the efficacy of Nanocurcumin Capsules by BiotexLife Solutions Private Limited. The final manuscript should indicate the funding sources and institutional affiliations as per the journal’s instructions while submitting this paper.

Conflict of Interest

The authors associated with any organisation mentioned in this article should disclose all financial, positional, consultative, and product-development relationships. Likewise, independent researchers should reveal any consultancy or honorarium related to this product analysis.

Ethical Approval

This article does not require an ethical approval statement since it is a narrative literature review that involves neither human subjects nor animals nor patient data.

Data Availability

This study did not produce any original data. This data availability statement highlights that the referenced peer-reviewed articles and journals support the scientific claims regarding the tested product. It is essential to confirm these claims with product-specific analytical data before finalising this manuscript for publication.

Regulatory Note

This article is solely for scientific literature review and research-validation purposes. It cannot be utilised as consumer health-care content about curcumin products without appropriate regulatory approvals from the local government agencies (FSSAI – Food Safety Standards Authority of India, EFSA – European Food Safety Authority, FDA – US – Food and Drug Administration).

Declaration of AI use

The authors employed generative AI tools only to a limited extent, specifically for grammar correction and language support while preparing the manuscript. All scientific content, analyses, and conclusions are solely the work of the authors; they reviewed and modified the output and assume complete responsibility for the final version of the manuscript.

References

[1] P. Anand, A.B. Kunnumakkara, R.A. Newman, B.B. Aggarwal, Bioavailability of Curcumin: Problems and Promises, Molecular Pharmaceutics 4 (2007) 807-818. https://doi.org/10.1021/mp700113r.

[2] S. Prasad, A.K. Tyagi, B.B. Aggarwal, Recent Developments in Delivery, Bioavailability, Absorption and Metabolism of Curcumin: the Golden Pigment from Golden Spice, Cancer Research and Treatment 46 (2014) 2-18. https://doi.org/10.4143/crt.2014.46.1.2.

[3] S.J. Stohs, O. Chen, S.D. Ray, J. Ji, L.R. Bucci, H.G. Preuss, Highly Bioavailable Forms of Curcumin and Promising Avenues for Curcumin-Based Research and Application: A Review, Molecules 25 (2020) 1397. https://doi.org/10.3390/molecules25061397.

[4] A. Karthikeyan, N. Senthil, T. Min, Nanocurcumin: A Promising Candidate for Therapeutic Applications, Frontiers in Pharmacology 11 (2020) 487. https://doi.org/10.3389/fphar.2020.00487.

[5] M. Gera, N. Sharma, M. Ghosh, D.L. Huynh, S. Lee, T. Min, T. Kwon, D.K. Jeong, Nanoformulations of curcumin: an emerging paradigm for improved remedial application, Oncotarget 8 (2017) 66680-66698. https://doi.org/10.18632/oncotarget.19164.

[6] J. Yakubu, A.V. Pandey, Innovative Delivery Systems for Curcumin: Exploring Nanosized and Conventional Formulations, Pharmaceutics 16 (2024) 637. https://doi.org/10.3390/pharmaceutics16050637.

[7] S. Jacob, F.S. Kather, M.A. Morsy, S.H.S. Boddu, M. Attimarad, J. Shah, P. Shinu, A.B. Nair, Advances in Nanocarrier Systems for Overcoming Formulation Challenges of Curcumin: Current Insights, Nanomaterials 14 (2024) 672. https://doi.org/10.3390/nano14080672.

[8] M.M. Yallapu, P.K.B. Nagesh, M. Jaggi, S.C. Chauhan, Therapeutic Applications of Curcumin Nanoformulations, The AAPS Journal 17 (2015) 1341-1356. https://doi.org/10.1208/s12248-015-9811-z.

[9] L.F. Laurindo, G.M. de Carvalho, B. de O. Zanuso, M.E. Figueira, R. Direito, R. de A. Goulart, D.S. Buglio, S.M. Barbalho, Curcumin-Based Nanomedicines in the Treatment of Inflammatory and Immunomodulated Diseases: An Evidence-Based Comprehensive Review, Pharmaceutics 15 (2023) 229. https://doi.org/10.3390/pharmaceutics15010229.

[10] T. Rigia, B. Banik, P. Sharma, R. Das, J.P. Mohanty, A comprehensive review on Nanocurcumin: Advances in bioavailability and therapeutic applications, Journal of Pharmacognosy and Phytochemistry 14 (2025) 192-202. https://doi.org/10.22271/phyto.2025.v14.i4c.15469.

[11] A.A.-S. Baqer, A.S.A. AlHassan, T.H. Ali, Curcumin and Its Nanoformulations: A Comprehensive Review of Anti-inflammatory and Antioxidant Properties, SAR Journal of Pathology and Microbiology 7 (2026) 29-32. https://doi.org/10.36346/sarjpm.2026.v07i01.005.

[12] J. Cui, H. Li, T. Zhang, F. Lin, M. Chen, G. Zhang, Z. Feng, Research progress on the mechanism of curcumin anti-oxidative stress based on signaling pathway, Frontiers in Pharmacology 16 (2025) 1548073. https://doi.org/10.3389/fphar.2025.1548073.

[13] Y. Peng, M. Ao, D. BaoHua, Y. Jiang, L. Yu, Z. Chen, C. Hu, R. Xu, Anti-Inflammatory Effects of Curcumin in the Inflammatory Diseases: Status, Limitations and Countermeasures, Drug Design Development and Therapy (2021) 4503-4525. https://doi.org/10.2147/dddt.s327378.

[14] S.T. Sorourozaman, F.A. Raed, M. Nuriddin, K. Oygul, R. Zilolakhon, H. Mehrigul, S.S. Mohammadhossein, M.S. Girish, S.D. Farhad, V. Shohreh, Curcumin in Redox and Inflammatory Signaling: Mechanistic Insights into NF-κB and Nrf2 Pathway Regulation, Journal of Chemical Health Risks (2025). https://doi.org/10.60829/jchr.2025.1203714.

[15] H.A. Saleh, M.H. Yousef, A. Abdelnaser, The Anti-Inflammatory Properties of Phytochemicals and Their Effects on Epigenetic Mechanisms Involved in TLR4/NF-κB-Mediated Inflammation, Frontiers in Immunology 12 (2021) 606069. https://doi.org/10.3389/fimmu.2021.606069.

[16] A. Karimi, S. Pourreza, M. Vajdi, A. Mahmoodpoor, S. Sanaie, M. Karimi, A. Tarighat-Esfanjani, Evaluating the effects of curcumin nanomicelles on clinical outcome and cellular immune responses in critically ill sepsis patients: A randomized, double-blind, and placebo-controlled trial, Frontiers in Nutrition 9 (2022) 1037861. https://doi.org/10.3389/fnut.2022.1037861.

[17] F.L. Arab, A. Hoseinzadeh, F. Mohammadi, A. Rajabian, A. Faridzadeh, M. Mahmoudi, Immunoregulatory effects of nanocurcumin in inflammatory milieu: Focus on COVID-19, Biomedicine & Pharmacotherapy 171 (2024) 116131. https://doi.org/10.1016/j.biopha.2024.116131.

[18] H. Rahim-Mahdy, R. Seifert, A market and risk assessment of 125 turmeric supplements available in Australia, Germany, India, UK, and USA, Naunyn-Schmiedeberg's Archives of Pharmacology 399 (2025) 1315-1346. https://doi.org/10.1007/s00210-025-04392-5.

[19] M. Esmaeli, M.D. Dehabadi, A. Ghanbari, Molecular targets and therapeutic implications of curcumin in hepatocellular carcinoma: a comprehensive literature review, Cancer Cell International 25 (2025) 335. https://doi.org/10.1186/s12935-025-03988-4.

[20] B. Wang, S. Hu, Y. Teng, J. Chen, H. Wang, Y. Xu, K. Wang, J. Xu, Y. Cheng, X. Gao, Current advance of nanotechnology in diagnosis and treatment for malignant tumors, Signal Transduction and Targeted Therapy 9 (2024) 200. https://doi.org/10.1038/s41392-024-01889-y.

[21] J. Sharifi-Rad, Y.E. Rayess, A.A. Rizk, et al., Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications, Frontiers in Pharmacology 11 (2020) 1021. https://doi.org/10.3389/fphar.2020.01021.

[22] P. Zhao, Y. Qi, Curcumin: A Comprehensive Review of Its Bioactivities, Therapeutic Potential, and Safety in Functional Food and Health Applications, Food Science and Human Wellness (2025). https://doi.org/10.26599/fshw.2025.9250810.

[23] M. Hegde, S. Girisa, B. BharathwajChetty, R. Vishwa, A.B. Kunnumakkara, Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?, ACS Omega 8 (2023) 10713-10746. https://doi.org/10.1021/acsomega.2c07326.

[24] A. Gdowski, K.V.B. Johnson, S. Shah, I. Gryczynski, J.K. Vishwanatha, A.P. Ranjan, Optimization and scale up of microfluidic nanolipomer production method for preclinical and potential clinical trials, Journal of Nanobiotechnology 16 (2018) 12. https://doi.org/10.1186/s12951-018-0339-0.

[25] H. Zhou, C.S. Beevers, S. Huang, The Targets of Curcumin, Current Drug Targets 12 (2011) 332-347. https://doi.org/10.2174/138945011794815356.

[26] M. Salem, S. Rohani, E.R. Gillies, Curcumin, a promising anti-cancer therapeutic: a review of its chemical properties, bioactivity and approaches to cancer cell delivery, RSC Advances 4 (2014) 10815. https://doi.org/10.1039/c3ra46396f.

[27] S.S. Patel, A. Acharya, R.S. Ray, R. Agrawal, R. Raghuwanshi, P. Jain, Cellular and molecular mechanisms of curcumin in prevention and treatment of disease, Critical Reviews in Food Science and Nutrition 60 (2019) 887-939. https://doi.org/10.1080/10408398.2018.1552244.

[28] T. Gupta, J. Singh, S. Kaur, S.K. Sandhu, G. Singh, I.P. Kaur, Enhancing Bioavailability and Stability of Curcumin Using Solid Lipid Nanoparticles (CLEN): A Covenant for Its Effectiveness, Frontiers in Bioengineering and Biotechnology 8 (2020) 879. https://doi.org/10.3389/fbioe.2020.00879.

[29] Z. Rafiee, M. Nejatian, M. Daeihamed, S.M. Jafari, Application of different nanocarriers for encapsulation of curcumin, Critical Reviews in Food Science and Nutrition 59 (2018) 3468-3497. https://doi.org/10.1080/10408398.2018.1495174.

[30] T.R. Charan, M.A. Bhutto, A.A. Tunio, G.M. Khuhro, S.A. Khaskheli, A.A. Mughal, Nanomaterials of curcumin-hyaluronic acid: various methods of formulations, clinical and therapeutic applications, present gap, and future directions, Future Journal of Pharmaceutical Sciences 7 (2021). https://doi.org/10.1186/s43094-021-00281-9.

[31] Z. Li, M. Shi, N. Li, R. Xu, Application of Functional Biocompatible Nanomaterials to Improve Curcumin Bioavailability, Frontiers in Chemistry 8 (2020) 589957. https://doi.org/10.3389/fchem.2020.589957.

[32] L. Zeng, T. Yang, K. Yang, G. Yu, J. Li, X. Wang, H. Chen, Efficacy and Safety of Curcumin and Curcuma longa Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial, Frontiers in Immunology 13 (2022) 891822. https://doi.org/10.3389/fimmu.2022.891822.

[33] D. Sun, J. Wang, X. Li, J. Peng, S. Wang, Advances and Perspectives in Curcumin Regulation of Systemic Metabolism: A Focus on Multi-Organ Mechanisms, Antioxidants 15 (2026) 109. https://doi.org/10.3390/antiox15010109.

[34] M. Boroughani, A.K. Moaveni, P. Hatami, N.M. Abasi, S.A. Seyedoshohadaei, A. Pooladi, Y. Moradi, R.R. Darehbagh, Nanocurcumin in cancer treatment: a comprehensive systematic review, Discover Oncology 15 (2024) 515. https://doi.org/10.1007/s12672-024-01272-x.

[35] M.J. Ernsting, M. Murakami, A. Roy, S. Li, Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles, Journal of Controlled Release 172 (2013) 782-794. https://doi.org/10.1016/j.jconrel.2013.09.013.

[36] J.L. Perry, K. Reuter, M.P. Kai, K.P. Herlihy, S. Jones, J.C. Luft, M.A. Napier, J.E. Bear, J.M. DeSimone, PEGylated PRINT Nanoparticles: The Impact of PEG Density on Protein Binding, Macrophage Association, Biodistribution, and Pharmacokinetics, Nano Letters 12 (2012) 5304-5310. https://doi.org/10.1021/nl302638g.

[37] S. Patel, S. Chekuri, R. Medhi, Enhancing Curcumin Bioavailability: A Systematic Review of Nanoparticle-Based Approaches, Digital Commons — PCOM (2025). https://digitalcommons.pcom.edu/research_day/research_day_PA_2025/researchPA2025/47.

[38] M. Rahban, M. Habibi-Rezaei, M. Mazaheri, L. Saso, A.A. Moosavi-Movahedi, Anti-Viral Potential and Modulation of Nrf2 by Curcumin: Pharmacological Implications, Antioxidants 9 (2020) 1228. https://doi.org/10.3390/antiox9121228.

[39] N.K. Grilc, M. Sova, J. Kristl, Drug Delivery Strategies for Curcumin and Other Natural Nrf2 Modulators of Oxidative Stress-Related Diseases, Pharmaceutics 13 (2021) 2137. https://doi.org/10.3390/pharmaceutics13122137.

[40] W.S. Sarawi, A.M. Alhusaini, L.M. Fadda, H.A. Alomar, A.B. Albaker, A.S. Aljrboa, A.M. Alotaibi, I.H. Hasan, A.M. Mahmoud, Nano-Curcumin Prevents Cardiac Injury, Oxidative Stress and Inflammation, and Modulates TLR4/NF-κB and MAPK Signaling in Copper Sulfate-Intoxicated Rats, Antioxidants 10 (2021) 1414. https://doi.org/10.3390/antiox10091414.

[41] M. Liu, J. Wang, Z. Song, Y. Pei, Regulation mechanism of curcumin mediated inflammatory pathway and its clinical application: a review, Frontiers in Pharmacology 16 (2025) 1642248. https://doi.org/10.3389/fphar.2025.1642248.

[42] K. Rahimi, A. Ahmadi, K. Hassanzadeh, Z. Soleimani, T. Sathyapalan, A. Mohammadi, A. Sahebkar, Targeting the balance of T helper cell responses by curcumin in inflammatory and autoimmune states, Autoimmunity Reviews 18 (2019) 738-748. https://doi.org/10.1016/j.autrev.2019.05.012.

[43] Y. Yuandani, I. Jantan, A.S. Rohani, I.B. Sumantri, Immunomodulatory Effects and Mechanisms of Curcuma Species and Their Bioactive Compounds: A Review, Frontiers in Pharmacology 12 (2021) 643119. https://doi.org/10.3389/fphar.2021.643119.

[44] M.V. Suresh, S. Francis, S. Aktay, G. Kralovich, K. Raghavendran, Therapeutic potential of curcumin in ARDS and COVID-19, Clinical and Experimental Pharmacology and Physiology 50 (2022) 267-276. https://doi.org/10.1111/1440-1681.13744.

[45] Z. Fan, J. Li, J. Liu, H. Jiao, B. Liu, Anti-Inflammation and Joint Lubrication Dual Effects of a Novel Hyaluronic Acid/Curcumin Nanomicelle Improve the Efficacy of Rheumatoid Arthritis Therapy, ACS Applied Materials & Interfaces 10 (2018) 23595-23604. https://doi.org/10.1021/acsami.8b06236.

[46] Z. Ghorbani, A. Hekmatdoost, P. Mirmiran, Anti-Hyperglycemic and Insulin Sensitizer Effects of Turmeric and Its Principle Constituent Curcumin, International Journal of Endocrinology and Metabolism 12 (2014). https://doi.org/10.5812/ijem.18081.

[47] H. Chi, X. Zhang, Z. Chen, Q. Chen, B. Yang, H. Deng, D. Yu, Lymph-Targeted Delivery of CUR-NLCs Enhances Oral Bioavailability: Evidence from a Double-Catheterized Rat Model, Pharmaceutics 17 (2025) 1484. https://doi.org/10.3390/pharmaceutics17111484.

[48] C.-H. Lin, C. Chen, Z. Lin, J. Fang, Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers, Journal of Food and Drug Analysis 25 (2017) 219-234. https://doi.org/10.1016/j.jfda.2017.02.001.

[49] M.A.S. Abourehab, S. Pramanik, M.A. Abdelgawad, B.M. Abualsoud, A. Kadi, M.J. Ansari, A. Deepak, Recent Advances of Chitosan Formulations in Biomedical Applications, International Journal of Molecular Sciences 23 (2022) 10975. https://doi.org/10.3390/ijms231810975.

[50] X. Xie, Q. Tao, Y. Zou, F. Zhang, M. Guo, Y. Wang, H. Wang, Q. Zhou, S. Yu, PLGA Nanoparticles Improve the Oral Bioavailability of Curcumin in Rats: Characterizations and Mechanisms, Journal of Agricultural and Food Chemistry 59 (2011) 9280-9289. https://doi.org/10.1021/jf202135j.

[51] N. Kamaly, B. Yameen, J. Wu, O.C. Farokhzad, Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release, Chemical Reviews 116 (2016) 2602-2663. https://doi.org/10.1021/acs.chemrev.5b00346.

[52] N.A. D'Angelo, M.A. Noronha, I.S. Kurnik, et al., Curcumin encapsulation in nanostructures for cancer therapy: A 10-year overview, International Journal of Pharmaceutics 604 (2021) 120534. https://doi.org/10.1016/j.ijpharm.2021.120534.

[53] M. Rakotoarisoa, A. Angelova, Amphiphilic Nanocarrier Systems for Curcumin Delivery in Neurodegenerative Disorders, 2019, pp. 1027-1065. https://doi.org/10.1201/9780429295010-33.

[54] V. Verdoliva, M. Saviano, S.D. Luca, Spectroscopic study to assess the integrity of chemically modified curcumin: Hyaluronic acid-curcumin conjugate as a proof of the method, Journal of Photochemistry and Photobiology A Chemistry 453 (2024) 115665. https://doi.org/10.1016/j.jphotochem.2024.115665.

[55] M.A. Lebda, I.H. Elmassry, N. Taha, M. Elfeky, Nanocurcumin alleviate inflammation and oxidative stress in LPS-induced mastitis model via activation of Nrf2 and suppressing TLR4 mediated NF-κB and HMGB1 signaling pathways, Research Square (2021). https://doi.org/10.21203/rs.3.rs-447345/v1.

[56] P. Malik, T.K. Mukherjee, Structure-Function Elucidation of Antioxidative and Prooxidative Activities of the Polyphenolic Compound Curcumin, Chinese Journal of Biology 2014 (2014) 1-8. https://doi.org/10.1155/2014/396708.

[57] G.M. Pontes-Quero, L. Benito-Garzon, J.P. Cano, M.R. Aguilar, B. Vazquez-Lasa, Amphiphilic polymeric nanoparticles encapsulating curcumin: Antioxidant, anti-inflammatory and biocompatibility studies, Materials Science and Engineering C 121 (2020) 111793. https://doi.org/10.1016/j.msec.2020.111793.

[58] A. Liakopoulou, S. Letsiou, K. Avgoustakis, G.P. Patrinos, F.N. Lamari, S. Hatziantoniou, Curcumin-Loaded Lipid Nanocarriers: A Targeted Approach for Combating Oxidative Stress in Skin Applications, Pharmaceutics 17 (2025) 144. https://doi.org/10.3390/pharmaceutics17020144.

[59] Q. Ma, X. He, Molecular Basis of Electrophilic and Oxidative Defense: Promises and Perils of Nrf2, Pharmacological Reviews 64 (2012) 1055-1081. https://doi.org/10.1124/pr.110.004333.

[60] M.A. Mahlooji, A. Heshmati, N. Kheiripour, H. Ghasemi, S.S. Asl, G. Solgi, A. Ranjbar, A. Hosseini, Evaluation of Protective Effects of Curcumin and Nanocurcumin on Aluminium Phosphide-Induced Subacute Lung Injury in Rats: Modulation of Oxidative Stress through SIRT1/FOXO3 Signalling Pathway, Drug Research 72 (2021) 100-108. https://doi.org/10.1055/a-1647-2418.

[61] A. Rajasekar, T. Devasena, Facile Synthesis of Curcumin Nanocrystals and Validation of Its Antioxidant Activity Against Circulatory Toxicity in Wistar Rats, Journal of Nanoscience and Nanotechnology 15 (2014) 4119-4125. https://doi.org/10.1166/jnn.2015.9600.

[62] P. Gupta, C.T. Jordan, M.I. Mitov, D.A. Butterfield, J.Z. Hilt, T.D. Dziubla, Controlled curcumin release via conjugation into PBAE nanogels enhances mitochondrial protection against oxidative stress, International Journal of Pharmaceutics 511 (2016) 1012-1021. https://doi.org/10.1016/j.ijpharm.2016.07.071.

[63] X. Chen, V. Chenna, A. Maitra, S. Devaraj, Nanocurcumin attenuates inflammation by decreasing Toll-like receptor 2 and 4 expression and activity and promoting an anti-inflammatory macrophage phenotype (830.22), The FASEB Journal 28 (2014). https://doi.org/10.1096/fasebj.28.1_supplement.830.22.

[64] C. Chittasupho, K. Srisawad, P. Arjsri, R. Phongpradist, W. Tingya, C. Ampasavate, P. Limtrakul, Targeting Spike Glycoprotein S1 Mediated by NLRP3 Inflammasome Machinery and the Cytokine Releases in A549 Lung Epithelial Cells by Nanocurcumin, Pharmaceuticals 16 (2023) 862. https://doi.org/10.3390/ph16060862.

[65] N. Salah, Etude de la potentialisation de la curcumine par des nanoparticules pour traiter les maladies inflammatoires chroniques de l'intestin, theses.fr (ABES) (2022). http://www.theses.fr/2022ULILS045/document.

[66] X. Han, R. Luo, S. Qi, Y. Wang, L. Dai, W. Nie, M. Lin, H. He, N. Ye, C. Fu, Y. You, S.-L. Fu, F. Gao, Dual sensitive supramolecular curcumin nanoparticles in advanced yeast particles mediate macrophage reprogramming, ROS scavenging and inflammation resolution for ulcerative colitis treatment, Journal of Nanobiotechnology 21 (2023) 321. https://doi.org/10.1186/s12951-023-01976-2.

[67] J. Poles, E. Karhu, M. McGill, H.R. McDaniel, J.E. Lewis, The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: a narrative review, Journal of Clinical and Translational Research 7 (2021) 333-376. https://doi.org/10.18053/jctres.07.202103.004.

[68] A.B. Kunnumakkara, B.L. Sailo, K. Banik, C. Harsha, S. Prasad, S.C. Gupta, A.C. Bharti, B.B. Aggarwal, Chronic diseases, inflammation, and spices: how are they linked?, Journal of Translational Medicine 16 (2018) 14. https://doi.org/10.1186/s12967-018-1381-2.

[69] N. Kamaly, Z. Xiao, P.M. Valencia, A.F. Radovic-Moreno, O.C. Farokhzad, Targeted polymeric therapeutic nanoparticles: design, development and clinical translation, Chemical Society Reviews 41 (2012) 2971. https://doi.org/10.1039/c2cs15344k.

[70] P.M. Valencia, E.M. Pridgen, M. Rhee, R. Langer, O.C. Farokhzad, R. Karnik, Microfluidic Platform for Combinatorial Synthesis and Optimization of Targeted Nanoparticles for Cancer Therapy, ACS Nano 7 (2013) 10671-10680. https://doi.org/10.1021/nn403370e.

Review prepared for BiotexLife Solutions Private Limited as scientific documentation for the Nanocurcumin Capsules botanical nutraceutical formulation. All evidence claims are grounded in the cited peer-reviewed literature. This document does not constitute medical advice. Product-level clinical and regulatory claims should be pursued through appropriately designed, registered, and GCP-compliant studies consistent with applicable nutraceutical regulatory frameworks.